Efficacy News and Research

RSS

NIDA grants $3.3M to design vaccine conferring immunity to nicotine

A chemical component present in the nightshade family of plants is one of the world's most tenaciously addictive substances. It is the nicotine contained in tobacco and found in high concentrations in cigarettes. Smoking remains a global scourge; in the U.S. it is the leading source of preventable death.

3 Jul 2013

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders.

2 Jul 2013

FDA sends Complete Response Letter to Merck regarding investigational drug for insomnia

Merck, known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for suvorexant, Merck's investigational medicine for the treatment of insomnia.

2 Jul 2013

UNC scientists use GEMMs to develop biomarkers for molecular subtypes of human breast cancer

It's a GEMM of a system. Genetically engineered mouse models that is. Using them allows scientists to study cancer in a way that more naturally mimics how human tumors exist within the complex environment of the body.

2 Jul 2013

SBRT treatment safe and effective for stage I NSCLC, study finds

Stereotactic body radiotherapy is considered the treatment of choice for early-stage non-small-cell lung cancer if patients are inoperable because of additional medical conditions.

2 Jul 2013

OBI advances Phase IIb clinical trial of Oxycyte for treatment of TBI

Oxygen Biotherapeutics, Inc., ("OBI") (NASDAQ: OXBT), today announced enrollment of the first subject in the second cohort of its global Phase IIb clinical trial to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury ("STOP-TBI").

2 Jul 2013

New report shows steady progress in research and development for HIV vaccines

Recent breakthroughs in HIV prevention research have confirmed the promise of new options to help end the AIDS epidemic and highlight the urgent need for ongoing research to develop additional prevention options and support rapid rollout of proven ones.

1 Jul 2013

RPCI scientists assess safety and efficacy of immunotherapy approach to treat advanced melanoma

A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma. Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.

30 Jun 2013

Transplanted bone marrow stem cells in patients with type 2 diabetes reduce insulin use

A study carried out in India examining the safety and efficacy of self-donated (autologous), transplanted bone marrow stem cells in patients with type 2 diabetes (TD2M), has found that patients receiving the transplants, when compared to a control group of TD2M patients who did not receive transplantation, required less insulin post-transplantation.

30 Jun 2013

Innovative procedure for atrial fibrillation reduces risk for stroke

The UNC Center for Heart and Vascular Care is the first in North Carolina to use an innovative procedure for people at risk for stroke.

28 Jun 2013

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

28 Jun 2013

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira, the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use, recommending the European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

28 Jun 2013

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today positive topline clinical results from a 6-week randomized, double-masked, placebo-controlled Phase 1b/2a study of EBI-005 in patients with dry eye disease.

28 Jun 2013

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

The US Food and Drug Administration has expanded the approved indication for Exelon Patch (rivastigmine transdermal system) to include the treatment of people with severe Alzheimer's disease with Exelon Patch 13.3mg/24h.

28 Jun 2013

Autism Speaks funds high priority research for treatment of ASD

Autism Speaks, the world's leading autism science and advocacy organization, today announced awards totaling $685,968 funding new research in areas of high priority that will advance understanding and treatment of autism spectrum disorders (ASD).

27 Jun 2013

Edge Therapeutics announces positive preliminary results from EG-1962 study for prevention of DCI

Edge Therapeutics announced today positive preliminary results from the first human use of EG-1962, the Company's novel bioabsorbable nimodipine microparticle formulation for the prevention of delayed cerebral ischemia, a life-threatening complication of subarachnoid hemorrhage, typically resulting from a ruptured brain aneurysm or traumatic brain injury.

27 Jun 2013

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.

27 Jun 2013

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Ambit Biosciences Corporation announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were featured in multiple presentations at the 18th Congress of the European Hematology Association in Stockholm, Sweden.

27 Jun 2013

Physician’s unfavorable attitudes about opioid drugs linked with lower rates of prescribing

According to a study of physicians' attitudes about pain drugs published in The Journal of Pain, negative physician attitudes about opioid medications are closely associated with lower rates of prescribing and more favorable attitudes are linked with higher prescribing levels.

26 Jun 2013

Researchers develop breakthrough approach to reduce harmful effects from blood transfusions

Researchers from Case Western Reserve University School of Medicine have developed an unprecedented approach to restore nitric oxide to donated blood, a breakthrough that could dramatically reduce harmful effects from transfusions.

26 Jun 2013

Efficacy News and Research

NIDA grants $3.3M to design vaccine conferring immunity to nicotine

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

FDA sends Complete Response Letter to Merck regarding investigational drug for insomnia

UNC scientists use GEMMs to develop biomarkers for molecular subtypes of human breast cancer

SBRT treatment safe and effective for stage I NSCLC, study finds

OBI advances Phase IIb clinical trial of Oxycyte for treatment of TBI

New report shows steady progress in research and development for HIV vaccines

RPCI scientists assess safety and efficacy of immunotherapy approach to treat advanced melanoma

Transplanted bone marrow stem cells in patients with type 2 diabetes reduce insulin use

Innovative procedure for atrial fibrillation reduces risk for stroke

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

Autism Speaks funds high priority research for treatment of ASD

Edge Therapeutics announces positive preliminary results from EG-1962 study for prevention of DCI

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Physician’s unfavorable attitudes about opioid drugs linked with lower rates of prescribing

Researchers develop breakthrough approach to reduce harmful effects from blood transfusions

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News